Alector, Inc. (ALEC, Financial) saw a significant stock price drop of 5.15%, currently trading at $1.94 per share. The trading volume reached 477,885 shares, with a turnover rate of 0.49% and a price fluctuation of 5.88%. Recent financial reports show revenue of $15.34 million, a net loss of $42.22 million, and earnings per share of -$0.43. The company's gross profit stands at $13.15 million with a price-to-earnings ratio of -1.14. Among ten rating institutions, 80% recommend buying, while 20% suggest selling.
In the biotech industry, which dropped 0.66%, notable stocks include Cardio Diagnostics and Innate Pharma. Alector focuses on developing therapies for neurodegenerative diseases, with key products AL001, AL002, AL003, and AL101.
